Lipocine (NASDAQ:LPCN) Upgraded by StockNews.com to Buy

Lipocine (NASDAQ:LPCN) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Lipocine Price Performance

NASDAQ LPCN traded up $0.07 during trading on Friday, hitting $4.84. The company’s stock had a trading volume of 17,556 shares, compared to its average volume of 51,227. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $11.79. The company has a market cap of $25.88 million, a PE ratio of -2.83 and a beta of 1.21. The business’s 50 day simple moving average is $4.58 and its 200-day simple moving average is $5.52.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The company had revenue of $0.09 million for the quarter. Analysts expect that Lipocine will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.